AQR Capital Management LLC decreased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 39.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 203,280 shares of the company's stock after selling 131,494 shares during the period. AQR Capital Management LLC's holdings in Kenvue were worth $4,338,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Grove Bank & Trust lifted its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue in the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. boosted its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Asset Planning Inc bought a new stake in Kenvue in the fourth quarter worth $42,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Stock Up 1.9%
Kenvue stock traded up $0.45 during mid-day trading on Thursday, reaching $23.65. The stock had a trading volume of 7,304,893 shares, compared to its average volume of 17,035,464. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The company has a 50-day moving average price of $23.15 and a two-hundred day moving average price of $22.58. The company has a market capitalization of $45.37 billion, a price-to-earnings ratio of 44.67, a PEG ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter in the prior year, the company posted $0.28 earnings per share. The business's revenue for the quarter was down 3.9% on a year-over-year basis. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.47%. Kenvue's payout ratio is 149.09%.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on KVUE shares. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Barclays boosted their price target on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday. Finally, UBS Group upped their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average target price of $25.33.
Check Out Our Latest Stock Analysis on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
